PAR Formulations Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: PAR Formulations Private Limited Pharmaceutical Export Portfolio Dataset — 11 Products, $35.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

PAR Formulations Private Limited — Pharmaceutical Exporter Profile (2026) | 11 Products, $35.0M Trade | TransData Nexus

PAR Formulations Private Limited

Indian Pharmaceutical Exporter · Lipid & Metabolism Specialist · $35.0M Total Trade · DGFT Verified

PAR Formulations Private Limited is an Indian pharmaceutical exporter with a total trade value of $35.0M across 11 products in 8 therapeutic categories. Based on 727 verified export shipments from Indian Customs (DGFT) records, PAR Formulations Private Limited is the #1 Indian exporter in 1 product including Methylprednisolone. Top exports include Allopurinol ($10.6M), Propranolol ($5.5M), Lansoprazole ($4.8M).

PAR Formulations Private Limited — Export Portfolio & Destination Treemap

PAR Formulations Private Limited pharmaceutical export portfolio — 11 products across 8 therapeutic categories. Source: Indian Customs (DGFT).

Who is PAR Formulations Private Limited? — Company Overview & Market Position

PAR Formulations Private Limited, established on September 22, 1982, is a privately held pharmaceutical company headquartered in Chennai, Tamil Nadu, India. The company is registered under the Corporate Identification Number (CIN) U33111TN1982PTC009602. As of the latest available data, PAR Formulations has an authorized capital of ₹2.20 crore and a paid-up capital of ₹2.14 crore. The company employs approximately 1,304 professionals, reflecting its significant presence in the pharmaceutical manufacturing sector.

PAR Formulations specializes in the development and manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio spans 11 products across 8 therapeutic categories, with a notable concentration in the Lipid & Metabolism, Respiratory, and Cardiovascular segments. The top five products—Allopurinol, Propranolol, Lansoprazole, Prednisone, and Kit—collectively account for 79.6% of the company's total export value, indicating a focused approach in its product offerings.

What Does PAR Formulations Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Allopurinol$10.6M

Product Portfolio — Top 11 by Export Value

PAR Formulations Private Limited exports 11 pharmaceutical products across 8 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Allopurinol	Lipid & Metabolism	$10.6M	211	2.1%	5
2	Propranolol	Cardiovascular	$5.5M	109	9.4%	2
3	Lansoprazole	Gastrointestinal	$4.8M	95	1.6%	3
4	Prednisone	Respiratory	$4.7M	94	16.9%	2
5	Kit	Medical Devices & Diagnostics	$2.5M	49	0.6%	2
6	Methylprednisolone	Corticosteroids	$2.2M	44	7.5%	1
7	Prednisolone	Respiratory	$2.2M	44	2.3%	4
8	Colchicine	Lipid & Metabolism	$1.0M	20	4.7%	5
9	Isosorbide	Cardiovascular	$987.3K	44	2.2%	8
10	Aspirin	Analgesics & Antipyretics	$700.0K	14	1.9%	8
11	Alprazolam	CNS & Psychiatric	$59.0K	3	0.4%	14

PAR Formulations Private Limited exports 11 pharmaceutical products across 8 therapeutic categories with a total export value of $35.0M. The company is the #1 Indian exporter in 1 product: Methylprednisolone. The top category is Lipid & Metabolism (33.0% of portfolio), followed by Respiratory (19.7%), indicating a concentrated portfolio with the top 5 products accounting for 79.6% of total export value.

PAR Formulations Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

PAR Formulations operates manufacturing facilities in Chennai, Tamil Nadu, India. The company's plant locations are strategically situated to cater to both domestic and international markets. While specific details regarding manufacturing capacities and specializations are not publicly disclosed, the company's substantial export value of $35.0 million USD and a total of 727 shipments suggest a robust manufacturing infrastructure capable of meeting diverse production demands.

3Key Leadership

The leadership team at PAR Formulations includes:

Chitti Babu Sampath Kumar: Whole-Time Director, appointed on June 28, 2017.

Anand Amrit Raj: Director, appointed on May 27, 2022.

Jalaj Sharma: Director, appointed on October 21, 2015.

Robert Joseph Cobuzzi Jr.: Director, appointed on September 25, 2015.

Susan Teresa Hall: Director, appointed on September 26, 2016.

These individuals bring a wealth of experience and strategic vision to the company's operations, contributing to its growth and market presence.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does PAR Formulations Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

PAR Formulations has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has achieved approvals for its products in these regions, demonstrating compliance with stringent regulatory standards. Specific details regarding regulatory filings, approvals, and market access status are not publicly disclosed; however, the company's substantial export value and diverse product portfolio indicate successful penetration into these markets.

2Emerging Markets

PAR Formulations has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has facilitated access to these regions, enabling the supply of quality-assured pharmaceutical products. While specific market penetration details are not publicly available, the company's export activities suggest a growing footprint in these emerging markets.

3Geographic Strategy

PAR Formulations demonstrates a diversified geographic strategy, exporting products to various international markets. The company's substantial export value and the distribution of its product portfolio across multiple therapeutic categories indicate a balanced approach, mitigating concentration risks. This strategic direction positions the company to leverage opportunities in both established and emerging markets.

PAR Formulations Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

PAR Formulations' manufacturing facility in Dhar, India, is registered with the U.S. Food and Drug Administration (FDA), as indicated by the Facility Establishment Identifier (FEI) number 3016268582. The facility has undergone multiple FDA inspections, with the most recent conducted on March 26, 2024. Notably, no Form 483 observations were issued during this inspection, suggesting compliance with FDA standards. The absence of warning letters further reflects the facility's adherence to regulatory requirements. (atlas-compliance.ai)

2WHO & EU GMP

PAR Formulations has achieved compliance with World Health Organization (WHO) Good Manufacturing Practices (GMP) and holds European Union (EU) GMP certificates. These certifications affirm the company's commitment to maintaining high-quality manufacturing standards, ensuring the safety and efficacy of its pharmaceutical products in international markets.

3CDSCO & Indian Regulatory

In India, PAR Formulations holds manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO). The company has obtained approvals from state drug controllers and possesses export No Objection Certificates (NOCs), facilitating the export of its pharmaceutical products. These regulatory approvals underscore the company's compliance with national standards and its capability to supply products both domestically and internationally.

PAR Formulations Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

PAR Formulations operates in a competitive landscape, with several key players in the pharmaceutical manufacturing sector. While specific competitors are not identified in the available data, the company's substantial export value and diverse product portfolio suggest a strong position in the market. The company's focus on high-demand therapeutic categories, such as Lipid & Metabolism, Respiratory, and Cardiovascular, positions it favorably against competitors in these segments.

2Key Differentiators

PAR Formulations' key differentiators include its extensive experience in pharmaceutical manufacturing, adherence to international quality standards, and a diversified product portfolio across multiple therapeutic categories. The company's significant export value and market presence reflect its ability to meet global demand for quality pharmaceutical products.

3Strategic Position

PAR Formulations is strategically positioned as a manufacturer of generic pharmaceutical products, with a focus on high-demand therapeutic areas. The company's adherence to international quality standards and regulatory approvals underscores its commitment to delivering safe and effective medications. Looking ahead, PAR Formulations is well-positioned to expand its market presence and explore opportunities in emerging therapeutic areas, leveraging its manufacturing capabilities and regulatory compliance.

Buyer Due Diligence Brief — Evaluating PAR Formulations Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

PAR Formulations has demonstrated a strong track record in pharmaceutical manufacturing, with a substantial export volume and consistent product quality. The company's adherence to international quality standards and regulatory approvals indicates reliability and trustworthiness as a supplier. The absence of regulatory observations or warnings further reinforces its reputation for compliance and quality assurance.

2Certifications to Verify

Importers should verify the following certifications when considering PAR Formulations as a supplier:

FDA Registration: Confirm the facility's registration status with the U.S. FDA to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the company's adherence to World Health Organization Good Manufacturing Practices, ensuring product quality and safety.

EU GMP Certification: Ensure the company holds European Union Good Manufacturing Practices certification, indicating compliance with EU standards.

Frequently Asked Questions — PAR Formulations Private Limited

How many pharmaceutical products does PAR Formulations Private Limited export from India?

PAR Formulations Private Limited exports 11 pharmaceutical products across 8 therapeutic categories. The top exports are Allopurinol ($10.6M), Propranolol ($5.5M), Lansoprazole ($4.8M), Prednisone ($4.7M), Kit ($2.5M). Total export value is $35.0M.

What is PAR Formulations Private Limited's total pharmaceutical export value?

PAR Formulations Private Limited's total pharmaceutical export value is $35.0M, based on 727 verified shipments recorded in Indian Customs (DGFT) data.

In which products is PAR Formulations Private Limited the #1 Indian exporter?

PAR Formulations Private Limited is the #1 Indian exporter in 1 products: Methylprednisolone (7.5% market share).

What therapeutic categories does PAR Formulations Private Limited cover?

PAR Formulations Private Limited exports across 8 therapeutic categories. The largest are Lipid & Metabolism (33.0%, 2 products), Respiratory (19.7%, 2 products), Cardiovascular (18.4%, 2 products).

Get Full PAR Formulations Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.